cyclophosphamide + doxorubicin + fluorouracil + methotrexate + prednisone + vincristine

This is a combination chemotherapy regimen consisting of six agents: - Cyclophosphamide (an alkylating agent that cross-links DNA) - Doxorubicin (an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II) - Fluorouracil (a pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis) - Methotrexate (a folate analog antimetabolite that inhibits dihydrofolate reductase, blocking DNA synthesis) - Prednisone (a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects; also induces apoptosis in certain cancer cells) - Vincristine (a vinca alkaloid that binds tubulin, inhibiting microtubule formation and arresting mitosis) This specific six-drug combination does not correspond to a widely recognized or standard named regimen in current oncology practice. However, regimens containing subsets of these drugs—such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for lymphoma[3][5], or FAC/CMF regimens for breast cancer[6][10]—are well established. The addition of both fluorouracil and methotrexate to the CHOP backbone is unusual but may be considered in investigational protocols or highly individualized treatment plans. The mechanism of action involves multiple pathways targeting rapidly dividing cells through direct cytotoxicity via DNA damage/cross-linking, inhibition of nucleotide synthesis/metabolism, disruption of mitotic spindle formation, and induction of apoptosis.